These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31375477)

  • 1. Cytidine Diphosphate-Ribitol Analysis for Diagnostics and Treatment Monitoring of Cytidine Diphosphate-l-Ribitol Pyrophosphorylase A Muscular Dystrophy.
    van Tol W; van Scherpenzeel M; Alsady M; Riemersma M; Hermans E; Kragt E; Tasca G; Kamsteeg EJ; Pennings M; van Beusekom E; Vermeulen JR; van Bokhoven H; Voermans NC; Willemsen MA; Ashikov A; Lefeber DJ
    Clin Chem; 2019 Oct; 65(10):1295-1306. PubMed ID: 31375477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan.
    Gerin I; Ury B; Breloy I; Bouchet-Seraphin C; Bolsée J; Halbout M; Graff J; Vertommen D; Muccioli GG; Seta N; Cuisset JM; Dabaj I; Quijano-Roy S; Grahn A; Van Schaftingen E; Bommer GT
    Nat Commun; 2016 May; 7():11534. PubMed ID: 27194101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes.
    Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC
    Elife; 2021 Jan; 10():. PubMed ID: 33513091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCYT2 synthesizes CDP-glycerol in mammals and reduced PCYT2 enhances the expression of functionally glycosylated α-dystroglycan.
    Imae R; Manya H; Tsumoto H; Miura Y; Endo T
    J Biochem; 2021 Oct; 170(2):183-194. PubMed ID: 34255834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model.
    Tokuoka H; Imae R; Nakashima H; Manya H; Masuda C; Hoshino S; Kobayashi K; Lefeber DJ; Matsumoto R; Okada T; Endo T; Kanagawa M; Toda T
    Nat Commun; 2022 Apr; 13(1):1847. PubMed ID: 35422047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral ribose supplementation in dystroglycanopathy: A single case study.
    Thewissen RMJ; Post MA; Maas DM; Veizaj R; Wagenaar I; Alsady M; Kools J; Bouman K; Zweers H; Meregalli PG; van der Kooi AJ; van Doorn PA; Groothuis JT; Lefeber DJ; Voermans NC
    JIMD Rep; 2024 May; 65(3):171-181. PubMed ID: 38736632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice.
    Cataldi MP; Blaeser A; Lu P; Leroy V; Lu QL
    Mol Ther Methods Clin Dev; 2020 Jun; 17():271-280. PubMed ID: 31988979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
    Cataldi MP; Lu P; Blaeser A; Lu QL
    Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
    Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
    Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Post-translational Modification with Ribitol-Phosphate and Its Defect in Muscular Dystrophy.
    Kanagawa M; Kobayashi K; Tajiri M; Manya H; Kuga A; Yamaguchi Y; Akasaka-Manya K; Furukawa JI; Mizuno M; Kawakami H; Shinohara Y; Wada Y; Endo T; Toda T
    Cell Rep; 2016 Mar; 14(9):2209-2223. PubMed ID: 26923585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDP-glycerol inhibits the synthesis of the functional
    Imae R; Manya H; Tsumoto H; Osumi K; Tanaka T; Mizuno M; Kanagawa M; Kobayashi K; Toda T; Endo T
    J Biol Chem; 2018 Aug; 293(31):12186-12198. PubMed ID: 29884773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy.
    Kanagawa M; Toda T
    J Neuromuscul Dis; 2017; 4(4):259-267. PubMed ID: 29081423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy.
    Kuwabara N; Imae R; Manya H; Tanaka T; Mizuno M; Tsumoto H; Kanagawa M; Kobayashi K; Toda T; Senda T; Endo T; Kato R
    Nat Commun; 2020 Jan; 11(1):303. PubMed ID: 31949166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of genotype-phenotype correlation in Walker-Warburg syndrome with a novel
    Bayram N; Bayram AK; Per H; Gümüş H; Ozsaygili C; Doğan MS; Çağlayan AO
    Eur J Ophthalmol; 2022 Sep; 32(5):NP71-NP76. PubMed ID: 33977792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous reductase activities for the generation of ribitol-phosphate, a CDP-ribitol precursor, in mammals.
    Hoshino S; Manya H; Imae R; Kobayashi K; Kanagawa M; Endo T
    J Biochem; 2024 Mar; 175(4):418-425. PubMed ID: 38140954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition.
    Praissman JL; Willer T; Sheikh MO; Toi A; Chitayat D; Lin YY; Lee H; Stalnaker SH; Wang S; Prabhakar PK; Nelson SF; Stemple DL; Moore SA; Moremen KW; Campbell KP; Wells L
    Elife; 2016 Apr; 5():. PubMed ID: 27130732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory machinery for the functional dystroglycan glycosylation.
    Kondo Y; Okajima T
    J Biochem; 2023 Apr; 173(5):333-335. PubMed ID: 36760122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell endogenous activities of fukutin and FKRP coexist with the ribitol xylosyltransferase, TMEM5.
    Nishihara R; Kobayashi K; Imae R; Tsumoto H; Manya H; Mizuno M; Kanagawa M; Endo T; Toda T
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1025-1030. PubMed ID: 29477842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.
    Cataldi MP; Vannoy CH; Blaeser A; Tucker JD; Leroy V; Rawls R; Killilee J; Holbrook MC; Lu QL
    Mol Ther; 2023 Dec; 31(12):3478-3489. PubMed ID: 37919902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promiscuous binding pocket of SLC35A1 ensures redundant transport of CDP-ribitol to the Golgi.
    Ury B; Potelle S; Caligiore F; Whorton MR; Bommer GT
    J Biol Chem; 2021; 296():100789. PubMed ID: 34015330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.